Changes

Organogenesis is a corporation based in Canton, MA.<ref name='Organogenesis 2010'>{{cite webREFwebQuote | quote=The corporate headquarters and manufacturing facility are located in Canton, Massachusetts. | last= | first= | publisher=Organogenesis | work= | date=2010 | urltitle=Headquarters | url = http://www.organogenesis.com/about_us/headquarters.html | title = Headquarters | accessdate = 2011-03-06 | publisher = Organogenesis | quote = The corporate headquarters and manufacturing facility are located in Canton, Massachusetts.}}</ref> They profit from [[Apligraf]], which is a synthetic skin created from harvested foreskins.<ref name='Organogenesis 20102011'>{{cite webREFwebQuote | quote=Human keratinocytes and fibroblasts are derived from neonatal foreskins. | last= | first= | publisher=Organogenesis | work= | date=2011 | urltitle=Apligraf: How Is It Made? | url = http://www.apligraf.com/professional/what_is_apligraf/how_is_it_made/ | title = Apligraf: How Is It Made? | accessdate = 2011-03-06 | publisher = Organogenesis | quote = Human keratinocytes and fibroblasts are derived from neonatal foreskins

 ==Call for increase of foreskin harvesting== {{Quote boxCitation |title Title= We Must Be Able To Obtain Adequate Sources Of Supply |quote Text= We e manufacture Apligraf for commercial sale, as well as for use in clinical trials, at our Canton, Massachusetts facility. Among the fundamental raw materials needed to manufacture Apligraf are keratinocyte and fibroblast cells. Because these cells are derived from donated infant foreskin, they may contain human-borne pathogens. We perform extensive testing of the cells for pathogens, including the HIV or "AIDS" virus. Our inability to obtain cells of adequate purity, or cells that are pathogen-free, would limit our ability to manufacture sufficient quantities of our products. |source Author=| Source= -- Organogensis| lang=| before=| after=| Transcription=| Translation=| ref=<ref>[http://sec.edgar-online.com/organogenesis-inc/10-k-annual-report/2001/04/02/Section2.aspx Organogensis, 2001 Annual Report (Delaware: Organogenesis, 2001), p.8.] |align = center |width = 50% |quoted = yes</ref>

==Apligraph Oral== Organogenesis is presently seeking [[FDA ]] approval for [[Apligraph ]] Oral, a foreskin-derived product for the "treatment of surgically treated gingival and alveolar mucosal surface defects in adults."<ref> {{cite web REFweb | last= | first= | date=November 2011 | title=November 17, 2011: Cellular, Tissue and Gene Therapies Advisory Committee Meeting: Transcript | url = http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/CellularTissueandGeneTherapiesAdvisoryCommittee/UCM284112.pdf | title publisher= November 17, 2011: Cellular, Tissue and Gene Therapies Advisory Committee Meeting: Transcript | accessdate = 2011-12-20 | date = November 2011}}</ref>